Core Viewpoint - The announcement from Yahui Pharmaceutical (688176.SH) indicates that the Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis has yielded positive preliminary results [1] Group 1: Clinical Trial Results - APL-1401 is a potent and selective dopamine β-hydroxylase (DBH) inhibitor, which increases dopamine levels and decreases norepinephrine levels, restoring intestinal immune homeostasis [1] - The company plans to further evaluate the efficacy of this potential first-in-class therapy in a larger cohort of patients with moderate to severe active ulcerative colitis over a 12-week treatment period [1]